SAEDNEWS: MedPath, an international platform specializing in medical information, clinical trials, and health technologies, has published a report highlighting the development and approval of WhartoCell, a cell therapy product developed by the Royan Institute.
According to Saednews, WhartoCell is presented as an allogeneic, off-the-shelf cell-based therapeutic product derived from umbilical cord-derived mesenchymal stem cells (MSCs). The product has been developed as part of efforts to advance innovative cell therapy approaches for the treatment of joint disorders and osteoarthritis.
MedPath, an international specialized platform covering health information and the discovery and analysis of clinical-trial data, has highlighted the development pathway of WhartoCell in Iran and the role of Royan Institute in this scientific and technological achievement. The platform aggregates and structures clinical-trial information and health-related data from a range of scientific sources and international registries.
The development of WhartoCell illustrates Royan Institute’s approach to translating advances in cellular and molecular sciences into applicable technologies and medical products. The development pathway began with basic research and progressed through preclinical and clinical studies, process development and manufacturing, as well as the relevant regulatory procedures, bringing the product closer to potential therapeutic application.
The development process also demonstrates the institute’s capabilities in advancing cellular technologies and supporting the transition from scientific research to the development of cell therapy products with potential for clinical-scale application.
Lotfipanah, Director of Public Relations and International Affairs at Royan Institute, stated that the publication of the report on an international specialized health platform, together with Royan Institute’s scientific and research activities, reflects the growing international visibility of Iran’s scientific work in medical sciences and emerging health technologies.
He further noted that, over more than three decades of activity, Royan Institute has developed into one of Iran’s major centers in reproductive medicine, stem cell science, regenerative medicine, and biotechnology. According to Lotfipanah, the institute has pursued an integrated continuum of “research, technology, and service delivery,” linking these areas as interconnected stages in the development of scientific and medical applications.
The recognition of WhartoCell as a cell-based therapeutic product by specialized international sources and platforms, including MedPath, provides an opportunity to highlight Iran’s scientific and technological capabilities in cell therapy and to further develop Royan Institute’s engagement with the international scientific and technological community.
